FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186706039> ?p ?o ?g. }

• W3186706039 endingPage "e2860" @default.
• W3186706039 startingPage "e2860" @default.
• W3186706039 abstract "Effective treatment of acute myeloid leukemia (AML) is still controversial, therefore; a comprehensive understanding regarding the impaired cellular signaling pathways in AML can be useful in designing new therapeutic approaches. Among signaling pathways involved in AML, the mammalian target of rapamycin (mTOR) signaling pathway is of particular importance. While dysregulation of mTOR signaling has been reported in a wide range of patients with AML, but most studies have focused on mTOR downstream targets, and mTOR upstream targets have been overlooked.In this study, expression of mTOR genes and three upstream targets (5' adenosine monophosphate-activated protein kinase (AMPK, adiponectin, and sestrin 2) involved in mTOR signaling was investigated.In this study, expression of mTOR, AMPK, sestrin 2, and adiponectin genes in 60 patients with AML were evaluated compared to those of 30 healthy individuals as controls using the Real-Time polymerase chain reaction (Real-Time RT-PCR) method.According to the results, there was a significant difference in the expression of all the studied genes in patients in comparison to the normal control group (P <0.05). Expression of the mTOR gene was increased, while expression of AMPK, sestrin 2, and adiponectin genes was decreased in the patients with AML. Mean expression of the genes (2-ΔCt) (AMPK, sestrin 2, adiponectin, and mTOR) was equal to 7.9, 3.2, 3.74, and 1.49 for controls and 6, 2.1, 2.83, and 2.64 for patients with AML, respectively.Given the decreased expression levels of sestrin 2, adiponectin, and AMPK genes as tumor inhibitors and the increased expression level of the mTOR gene as an oncogene in the patients with AML in our study, it is thought that disruption of this pathway may be involved in leukemogenesis and can be considered as an effective factor in the progression of cancer." @default.
• W3186706039 created "2021-08-02" @default.
• W3186706039 creator A5002187912 @default.
• W3186706039 creator A5046050496 @default.
• W3186706039 creator A5060357296 @default.
• W3186706039 creator A5064932660 @default.
• W3186706039 creator A5069175966 @default.
• W3186706039 date "2021-04-01" @default.
• W3186706039 modified "2023-10-16" @default.
• W3186706039 title "Evaluation of Sestrin 2, Adiponectin, AMPK, and mTOR Genes Expression in Acute Myeloid Leukemia Patients." @default.
• W3186706039 cites W1559434684 @default.
• W3186706039 cites W1830885889 @default.
• W3186706039 cites W1892652667 @default.
• W3186706039 cites W1972618720 @default.
• W3186706039 cites W1977978614 @default.
• W3186706039 cites W1986915547 @default.
• W3186706039 cites W1991510903 @default.
• W3186706039 cites W2007757672 @default.
• W3186706039 cites W2012015257 @default.
• W3186706039 cites W2016107719 @default.
• W3186706039 cites W2058188142 @default.
• W3186706039 cites W2063504968 @default.
• W3186706039 cites W2068404779 @default.
• W3186706039 cites W2068661213 @default.
• W3186706039 cites W2079172266 @default.
• W3186706039 cites W2100140007 @default.
• W3186706039 cites W2102536308 @default.
• W3186706039 cites W2107277218 @default.
• W3186706039 cites W2110928985 @default.
• W3186706039 cites W2114570899 @default.
• W3186706039 cites W2117630883 @default.
• W3186706039 cites W2118519201 @default.
• W3186706039 cites W2121190158 @default.
• W3186706039 cites W2131888987 @default.
• W3186706039 cites W2146788325 @default.
• W3186706039 cites W2340761255 @default.
• W3186706039 cites W2497437482 @default.
• W3186706039 cites W2553673589 @default.
• W3186706039 cites W2581990988 @default.
• W3186706039 cites W2592973432 @default.
• W3186706039 cites W2593816418 @default.
• W3186706039 cites W2622950952 @default.
• W3186706039 cites W2734329550 @default.
• W3186706039 cites W2743018412 @default.
• W3186706039 cites W2756171353 @default.
• W3186706039 cites W2900535305 @default.
• W3186706039 cites W2923084788 @default.
• W3186706039 cites W2938390097 @default.
• W3186706039 cites W2981106301 @default.
• W3186706039 cites W1964184380 @default.
• W3186706039 doi "https://doi.org/10.30498/ijb.2021.2860" @default.
• W3186706039 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8358177" @default.
• W3186706039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34435062" @default.
• W3186706039 hasPublicationYear "2021" @default.
• W3186706039 type Work @default.
• W3186706039 sameAs 3186706039 @default.
• W3186706039 citedByCount "2" @default.
• W3186706039 countsByYear W31867060392022 @default.
• W3186706039 countsByYear W31867060392023 @default.
• W3186706039 crossrefType "journal-article" @default.
• W3186706039 hasAuthorship W3186706039A5002187912 @default.
• W3186706039 hasAuthorship W3186706039A5046050496 @default.
• W3186706039 hasAuthorship W3186706039A5060357296 @default.
• W3186706039 hasAuthorship W3186706039A5064932660 @default.
• W3186706039 hasAuthorship W3186706039A5069175966 @default.
• W3186706039 hasConcept C126322002 @default.
• W3186706039 hasConcept C184235292 @default.
• W3186706039 hasConcept C2776782570 @default.
• W3186706039 hasConcept C2777391703 @default.
• W3186706039 hasConcept C2778729363 @default.
• W3186706039 hasConcept C2779306644 @default.
• W3186706039 hasConcept C2780124434 @default.
• W3186706039 hasConcept C502942594 @default.
• W3186706039 hasConcept C62478195 @default.
• W3186706039 hasConcept C71924100 @default.
• W3186706039 hasConcept C75217442 @default.
• W3186706039 hasConcept C86554907 @default.
• W3186706039 hasConcept C86803240 @default.
• W3186706039 hasConcept C95444343 @default.
• W3186706039 hasConcept C97029542 @default.
• W3186706039 hasConceptScore W3186706039C126322002 @default.
• W3186706039 hasConceptScore W3186706039C184235292 @default.
• W3186706039 hasConceptScore W3186706039C2776782570 @default.
• W3186706039 hasConceptScore W3186706039C2777391703 @default.
• W3186706039 hasConceptScore W3186706039C2778729363 @default.
• W3186706039 hasConceptScore W3186706039C2779306644 @default.
• W3186706039 hasConceptScore W3186706039C2780124434 @default.
• W3186706039 hasConceptScore W3186706039C502942594 @default.
• W3186706039 hasConceptScore W3186706039C62478195 @default.
• W3186706039 hasConceptScore W3186706039C71924100 @default.
• W3186706039 hasConceptScore W3186706039C75217442 @default.
• W3186706039 hasConceptScore W3186706039C86554907 @default.
• W3186706039 hasConceptScore W3186706039C86803240 @default.
• W3186706039 hasConceptScore W3186706039C95444343 @default.
• W3186706039 hasConceptScore W3186706039C97029542 @default.
• W3186706039 hasIssue "2" @default.
• W3186706039 hasLocation W31867060391 @default.
• W3186706039 hasOpenAccess W3186706039 @default.

• next